Owkin has announced the spin out of Waiv, previously known as Owkin Dx, supported by $33 million in financing led by OTB Ventures and Alpha Intelligence Capital. The transaction reflects increased investor interest in AI-enabled precision diagnostics and positions Waiv as an independent company focused on patient identification and stratification in both clinical practice and clinical trials.
Waiv develops AI-powered precision tests designed to predict biomarkers and patient outcomes. Its portfolio includes RlapsRisk BC for prognostic risk profiling, and the company reports that multiple tests are already in use in clinical settings. Through its deployment platform, Destra, and collaborations with pharmaceutical partners—including MSD since 2023 for MSIntuit—Waiv is expanding the translational application of medical AI in oncology.
“The spin out of Waiv represents the natural evolution of our strategy to validate AI in the real world,” said Thomas Clozel, CEO and Co-founder of Owkin. “It's not enough to build models. You need feedback from real world applications to continuously improve the AI, ensuring models work for all patients in actual clinical workflows.”
Waiv builds on more than a decade of Owkin’s medical AI research, leveraging access to a broad patient data network and proprietary multimodal AI models. As an independent entity, Waiv will continue to operate as a strategic partner within Owkin’s broader patient validation ecosystem. That ecosystem includes patient-derived organoid testing and Owkin’s therapeutic clinical trial INVOKE, which targets triple inhibition of EP2, EP4, and DP1 with its first-in-class phase 1 candidate, OKN4395.
Owkin states that the combination of AI modeling, laboratory validation, and clinical trial integration is designed to create a feedback loop that strengthens real-world validation and supports the development of proprietary intellectual property.
“Waiv brings the scalability and speed of AI to oncology testing, while enabling drug developers to access insights that were previously out of reach,” said Meriem Sefta, CEO and Co-founder, Waiv. “Our goal is to make AI-enabled precision testing the global standard.”
The spinout follows Owkin’s earlier incubation of Bioptimus in February 2024 and represents a continued strategy of translating AI innovation into validated clinical applications.
Click here for the original news story.